A Central Role for Tumor-derived Monocyte Chemoattractant Protein-1 in Malignant Pleural Effusion

Georgios T. Stathopoulos(Vanderbilt University), Ioannis Psallidas(Vanderbilt University), Ardiana Moustaki(Vanderbilt University), C. Moschos(Vanderbilt University), Androniki Kollintza(Vanderbilt University), Sophia P. Karabela(Vanderbilt University), Ilias Porfyridis(Vanderbilt University), Spyridoula Vassiliou(Vanderbilt University), M. Karatza(Vanderbilt University), Zongmin Zhou(Vanderbilt University), Myungsoo Joo(Vanderbilt University), T.S. Blackwell(Vanderbilt University), Charalambos Roussos(Vanderbilt University), Daniel Graf(Vanderbilt University), Ioannis Kalomenidis(Vanderbilt University)
JNCI Journal of the National Cancer Institute
October 7, 2008
Cited by 97Open Access
Full Text

Abstract

BACKGROUND: Tumor cells in malignant pleural effusions (MPEs) are an important source of monocyte chemoattractant protein (MCP)-1. However, the role of tumor-derived MCP-1 in the pathogenesis and progression of MPE has not been determined. METHODS: B16 mouse skin melanoma cells, which are deficient in MCP-1 expression, and mouse Lewis lung cancer (LLC) cells, which express high levels of MCP-1, were engineered to stably express MCP-1 and short hairpin RNAs (shRNAs) targeting the MCP-1 transcript, respectively. Cells were injected into the pleural cavities of syngeneic immunocompetent mice, and MPE volume and pleural tumors were quantified at necropsy (day 14). MCP-1 and other mediators were determined by cytometric bead array and enzyme-linked immunosorbent assay, and mononuclear and endothelial cells were identified by immunolabeling of F4/80 and factor VIII-related antigen respectively. Mouse survival was assessed using Kaplan-Meier analysis. Vascular permeability in mice with MPE was assessed using albumin-binding Evans blue. Statistical tests were two-sided. RESULTS: LLC cells expressing shRNA against MCP-1 elaborated less than 5% of the MCP-1 level in cells expressing nonspecific shRNA (control cells), and intrapleural delivery of these cells resulted in less MPE (mean MPE volume = 86 and 585 muL, respectively; difference = 499 muL; 95% confidence interval [CI] = 331 to 669 muL; P < .001), reduced MCP-1 levels in the pleural fluid, and lower mortality than when control cells were delivered. Overexpression of MCP-1 in intrapleurally injected B16 melanoma cells led to increased MPE and reduced survival. In mice with MPE, MCP-1 was a potent inducer of vascular permeability, mononuclear recruitment, and, in pleural tumors, of angiogenesis. CONCLUSION: MCP-1 produced by tumor cells is an important determinant of their capacity to induce the formation of MPE and may be a useful target for the treatment of malignant pleural disease.


Related Papers

No related papers found

Powered by citation graph analysis